سعر فاسينرا 30 مجم/مل قلم معبأ 1 مل 2025

Benralizumab 30 mg/ml solution for subcutaneous injection in a 1 ml prefilled pen (AstraZeneca), single pen.

• Add-on maintenance treatment of severe asthma with an eosinophilic phenotype; not for relief of acute bronchospasm or status asthmaticus.Population: Patients 6 years and olderDailyMed (U.S. NLM)
• Eosinophilic granulomatosis with polyangiitis (EGPA).Population: AdultsDailyMed (U.S. NLM)
• Hypereosinophilic syndrome (HES).Population: Patients 12 years and olderDailyMed (U.S. NLM)

• Asthma: most common adverse reactions are headache and pharyngitis; in HES, hypersensitivity reactions and influenza-like illness were also common.International label, same formulation · DailyMed (U.S. NLM)

• Known hypersensitivity to benralizumab or excipients.International label, same formulation · DailyMed (U.S. NLM)

• Hypersensitivity reactions (anaphylaxis, angioedema, urticaria, rash) can occur; discontinue if severe. Do not use to treat acute asthma symptoms; do not abruptly discontinue systemic or inhaled corticosteroids after starting; treat pre-existing helminth infections before starting.International label, same formulation · DailyMed (U.S. NLM)

• Insufficient human data to evaluate drug-associated risk; IgG antibodies cross the placenta increasingly in the third trimester; no fetal harm in monkey studies.International label, same formulation · DailyMed (U.S. NLM)
• No information on presence in human milk or effects on the breastfed infant or milk production.International label, same formulation · DailyMed (U.S. NLM)

• Benralizumab: Binds IL-5 receptor alpha on eosinophils and basophils and induces their depletion through antibody-dependent cell-mediated cytotoxicity (US label).